多西他赛为主的联合方案治疗晚期乳腺癌疗效观察

目的：观察多西他赛为主方案治疗晚期乳腺癌的疗效及不良反应。方法：共有46例晚期乳腺癌患者接受治疗。初次化疗者及既往未使用过蒽环类者24例,接受多西他赛加吡柔吡星方案化疗,吡柔吡星40mg·（m^2）^-1,静脉冲入,第1天,多西他赛75mg·（m^2）^-1,静脉滴注1小时,第2天;既往使用过蒽环类治疗失败者22例,接受多西他赛加顺铂方案化疗,多西他赛75mg·（m^2）^-1,静脉滴注1小时,第1天,顺铂25～30mg·（m^2）^-1,静脉滴注,第2～5天。至少化疗2个周期以后评价疗效,按WHO标准进行评价。结果：46例患者CR3例,PR21例,NC13例,PD9例,有效率52.2%（24/46）,毒性反应主要为骨髓抑制和脱发。结论：多西他赛为主化疗方案治疗晚期乳腺癌疗效确切,毒性反应能耐受。

Efficacy and Safety of Combination Chemotherapy Based on Docetaxel for Advanced Breast Cancer

OBJECTIVE： To observe the efficacy and toxicity of docetaxel - based combination chemotherapy for advanced breast cancer. METHODS ： A total of 46 patients with advanced breast cancer were enrolled, of whom, 24 who had never been treated with anthracene nucleus were initially treated with pirarubicin 40 mg·（m^2）^-1 by intravenous injection on day 1 followed by 1 hour＇ s intravenous drop infusion of Docetaxel 75 mg·（m^2）^-1 on day 2 ; another 22 cases who had been treated with anthracene nucleus but failed to show response were given Docetaxel 75 mg·（m^2）^-1 by drip infusion for 1 hour on day 1 followed by drip infusion of cisplatin 25-30 mg·（m^2）^-1 from day 2 to day 5. After treatment for at least two courses, the clinical response of patients was evaluated based on criteria recommended by WHO. RESULTS： Of the 46 patients following treatment with docetaxel - based combined chemotherapy, the numbers of patients showing complete response （CR）, partial response （PR）, NC, progressive disease （PD） were 3, 21, 13, and 9, respectively, and the overall response rate was 52.2% （24/46）. The major toxicities were myelosuppression and alopecia. CONCLUSION： The docetaxel- based combined chemotherapy is effective and tolerable in patients with advanced breast cancer.